Pharmacogenet Genomics 2021 May 14. Epub 2021 May 14.
Institute of Pharmacogenetics Department of Nephrology Institute of Diagnostic and Interventional Radiology and Neuroradiology Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen Center for Translational Medicine, Ruhr University Bochum, Herne Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Aachen RWTH Centralized Biomaterial Bank (RWTH cBMB), Medical Faculty Department of Pneumology and Intensive Care Medicine, University Hospital Aachen, RWTH Aachen University, Aachen, Center of Emergency Medicine Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University of Duisburg-Essen, Essen Department of Nephrology, Ruhr University Bochum, Herne Center of Nephrology Mettmann, Mettmann Department of Pulmonary Medicine, Ruhrlandklinik, University Hospital Essen Institute of Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
Objectives: The RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Cell entry is mediated by the human angiotensin-converting enzyme II (ACE2). ACE2 and its close homolog angiotensin-converting enzyme I (ACE) are currently discussed candidate genes, in which single-nucleotide polymorphisms (SNPs) could alter binding or entry of SARS-CoV-2 and enhance tissue damage in the lung or other organs. Read More